ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 5 syntheses or guidelines pooled it, 224 citations in OpenAlex.
- Infective Endocarditis byPathogens (Basel, Switzerland) · 2025Pooled it
- Gut bacterial profiles in Parkinson's disease: A systematic review.CNS neuroscience & therapeutics · 2023Pooled it
- Time to abandon ampicillin plus gentamicin in favour of ampicillin plus ceftriaxone in Enterococcus faecalis infective endocarditis? A meta-analysis of comparative trials.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Pooled it
- A comparison of different antibiotic regimens for the treatment of infective endocarditis.The Cochrane database of systematic reviews · 2020Pooled it
- Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.Antimicrobial agents and chemotherapy · 2019Pooled it
- Comparative genomic characterization and antimicrobial resistance of bacteremia-causingMicrobiology spectrum · 2026Article
- The Pharmacology of Bacterial Persistence: From Antibiotic Tolerance to Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Next-Generation Strategies to Encounter Antimicrobial Resistance (AMR): From Lariocidin to Gene Editing and Nanotechnology-Based Approaches.Molecules (Basel, Switzerland) · 2026Review
- Data mining reveals the diversity of prophage endolysins targeting pathogenic enterococci.The Journal of general virology · 2026Article
- Optimal vancomycin AUCEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Isolation and characterization of Enterococcus phages vB_EfaS_785CC and vB_EfaS_785CS.Functional & integrative genomics · 2026Article
- Daptomycin and linezolid salvage therapy for persistent ampicillin-susceptibleJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026Article
- ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Extracellular vesicles derived from Enterococcus faecalis: inflammatory activation does not require internalization.Cell communication and signaling : CCS · 2026Article
- Biological characteristics and genome analysis of Enterococcus faecalis phage vB_EfS_L1.Archives of microbiology · 2026Article
- Antibacterial and Antifungal Potential of Hermetia illucens Hemolymph Contained-Peptides.Probiotics and antimicrobial proteins · 2026Article
- Ceftobiprole alone versus ampicillin-ceftriaxone against borderline-penicillin-resistant, ampicillin-susceptible, and vancomycin-resistantAntimicrobial agents and chemotherapy · 2026Article
- Management of Infective Endocarditis: A Scoping Review.Journal of Brown hospital medicine · 2026Review
- Linezolid and levofloxacin: an uncommon pairing that suppresses evolution of resistance inFEMS microbes · 2026Article
- Molecular Profiling of CRISPR-Cas System, Virulence Traits, and Antimicrobial Resistance inInternational journal of microbiology · 2026Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Enterococci, one of the most common causes of hospital-associated infections, are responsible for substantial morbidity and mortality. Enterococcus faecalis, the more common and virulent species, causes serious high-inoculum infections, namely infective endocarditis, that are associated with cardiac surgery and mortality rates that remained unchanged for the last 30 years. The best cures for these infections are observed with combination antibiotic therapy; however, optimal treatment has not been fully elucidated. It is the purpose of this review to highlight treatment options and their limitations, and provide direction for future investigative efforts to aid in the treatment of these severe infections. While ampicillin plus ceftriaxone has emerged as a preferred treatment option, mortality rates continue to be high, and from a safety standpoint, ceftriaxone, unlike other cephalosporins, promotes colonization with vancomycin resistant-enterococci due to high biliary concentrations. More research is needed to improve patient outcomes from this high-mortality disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.